

## ARTICLE

# Protective Effect of *Lactobacillus fermentum* LA12 in an Alcohol-Induced Rat Model of Alcoholic Steatohepatitis

Byoung-Kook Kim<sup>†</sup>, In-Ock Lee<sup>1†</sup>, Pei-Lei Tan<sup>1</sup>, Ju-Young Eor<sup>1</sup>, Jae-Kwan Hwang\*, and Sae-Hun Kim<sup>1\*</sup>

Department of Biotechnology & Department of Biomaterials Science and Engineering, Yonsei University, Seoul 03722, Korea

<sup>1</sup>Department of Food Bioscience and Technology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea



Received October 4, 2017  
Revised November 22, 2017  
Accepted December 4, 2017

\*Corresponding author

Jae-Kwan Hwang  
Department of Biotechnology &  
Department of Biomaterials Science  
and Engineering, Yonsei University,  
Seoul 03722, Korea  
Tel: +82-2-2123-5881  
Fax: +82-2-362-7265  
E-mail: jkhwang@yonsei.ac.kr

Sae-Hun Kim  
Department of Food Bioscience  
and Technology, College of Life Sci-  
ences and Biotechnology, Korea  
University, Seoul 02841, Korea  
Tel: +82-2-3290-3055  
Fax: +82-2-3290-3506  
E-mail: saehkim@korea.ac.kr

<sup>†</sup>These authors contributed equally in  
this work.

Copyright © Korean Society for Food  
Science of Animal Resources

This is an open access article distri-  
buted under the terms of the Creat-  
ive Commons Attribution Non-Com-  
mercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which  
permits unrestricted non-commercial  
use, distribution, and reproduction in  
any medium, provided the original  
work is properly cited.

## Abstract

Alcoholic liver disease (ALD) is a complex multifaceted disease that involves oxidative stress and inflammation as the key mediators. Despite decades of intensive research, there are no FDA-approved therapies, and/or no effective cure is yet available. Probiotics have received increasing attention in the past few years due to their well-documented gastrointestinal health-promoting effects. Interestingly, emerging studies have suggested that certain probiotics may offer benefits beyond the gut. *Lactobacillus fermentum* LA12 has been previously demonstrated to play a role in inflammatory-related disease. However, the possible protective effect of *L. fermentum* LA12 on ALD still remain to be explored. Thus, the aim of this study was to evaluate the possible protective effect of *L. fermentum* LA12 on alcohol-induced gut barrier dysfunction and liver damage in a rat model of alcoholic steatohepatitis (ASH). Daily oral administration of *L. fermentum* LA12 in rat model of ASH for four weeks was shown to significantly reduce intestinal nitric oxide production and hyperpermeability. Moreover, small intestinal histological- and qRT-PCR analysis further revealed that *L. fermentum* LA12 treatment was capable of up-regulating the mRNA expression levels of tight junction proteins, thereby stimulating the restitution of barrier structure and function. Serum and hepatic analyses also revealed that the restoration of epithelial barrier function may prevent the leakage of endotoxin into the blood, subsequently improve liver function and hepatic steatosis in the *L. fermentum* LA12-treated rats. Altogether, results in this study suggest that *L. fermentum* LA12 may be used as a dietary adjunct for the prevention and treatment of ASH.

**Keywords** alcoholic steatohepatitis, probiotics, *Lactobacillus fermentum* LA12, intestinal permeability, inflammation, oxidative stress, liver health

## Introduction

Liver disease remains as a major cause of morbidity and mortality throughout the world. World Health Organization (2014) has recently reported global liver disease burden and 5.9% (about 3.3 million) of all death worldwide were mainly attributable to alcohol. Excessive alcohol consumption is directly associated with an increased risk of ALD. In Korea, the amount of alcohol consumption has been increased from 8.38 L/capita in the year 2000 to 8.54 L/capita in the year 2009 (Bang *et al.*, 2015). Moreover, the alcohol consumption per capita is also tends to increase gradually in the future, thereby accelerating the risk of development of

ALD and liver-related mortality on heavy drinkers.

ALD is a complex advanced disease that associates with a wide spectrum of hepatic lesions, from steatosis and steatohepatitis to fibrosis and cirrhosis (Louvet and Mathurin, 2015). Steatosis and steatohepatitis are potentially reversible by timely treatment. Indeed, the reversibility of both steatosis and steatohepatitis has been demonstrated experimentally via animal models of ALD (Lu *et al.*, 2012). ASH, in particular, is one of the most common form of all the alcohol-related liver lesions. A growing body of literature has suggested that multiple pathogenic factors are involved in the development of ASH. Excessive alcohol intake can induce the generation of reactive oxygen species that disrupts hepatocyte metabolism, which contributes to hepatocyte injury (Szabo, 2015). In addition to reactive oxygen species, bacterial endotoxin (lipopolysaccharide) and nitric oxide have also been recently recognized as major factors that contribute to the abnormal gut-liver axis in ASH. Elevated levels of both bacterial endotoxin and nitric oxide mediated inflammation and altered immunology defense mechanisms and homeostasis in the gut-liver axis (Rao, 2009). These complications subsequently result in impaired intestinal barrier function and integrity, as well as liver damage in ASH. Thus, therapeutic strategies targeting specific pathways to restore liver function, and to reduce nitric oxide levels, development of intestinal hyperpermeability, and pro-inflammatory signal that contributes to inflammation in ASH could limit the progression of fibrosis.

Probiotics are “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (Hill *et al.*, 2014). Administration of host-derived probiotics are increasing globally, attributed to increased consumer interest in natural health-enhancing resources for treatment of various diseases. Despite host-derived probiotics have been well documented for the treatment and/or prevention of gastrointestinal disorders, a growing number of clinical studies propose that these microorganisms have therapeutic potentials beyond gut health. Probiotic microorganisms exert various gut health benefits mainly through the modulation of gut microbiota and production of bioactive metabolites. Owing to the close anatomical and functional relationship between gut and the liver; these could fundamentally extend the impact of probiotics on liver health. Interestingly, the interaction between the host-derived probiotic strains and the gut-liver axis has been the major focus of attention in the emerging trends for the treatment of ASH. It has been

demonstrated that host-derived *L. rhamnosus* GG could reduce intestinal oxidative stress and prevent increased intestinal permeability, leading to ameliorated ASH in rats (Forsyth *et al.*, 2009). Furthermore, oral administration of heat-killed *L. brevis* SBC8803 also capable of inhibiting gut-derived endotoxin migration into the liver, and thereby improve alcohol-induced liver injury in rats (Segawa *et al.*, 2008). These animal studies collectively suggested that host-derived *Lactobacillus* strains have the potential to be represented as promising therapeutic agents to prevent ASH and its related complications. Although promising, more studies are needed to better delineate the protective effect of these strains on ASH.

Previous studies have reported that *L. fermentum* LA12 isolated from Korean infant feces exhibited immune modulatory activities and was capable of extending lifespan in a nematodal model organism (Lee *et al.*, 2011); demonstrating its therapeutic potential for the treatments of inflammatory-related diseases. However, the possible protective effect of *L. fermentum* LA12 on ASH remains to be described. Therefore, the aim of the present study was to evaluate the effect of daily oral administration of *L. fermentum* LA12 on intestinal barrier function and liver function in a rat model of ASH.

## Materials and Methods

### Bacterial culture

Pure culture of *L. fermentum* LA12 was obtained from the Food Microbiology Laboratory, College of Life Sciences and Biotechnology, Korea University (Korea). *L. fermentum* LA12 was activated successfully three times in *Lactobacillus* de Man, Rogosa and Sharpe (MRS) broth (Difco, USA) at 37°C for 20 h prior to use. Stock culture was suspended in sterile 50% (v/v) glycerol and stored at -80°C until further use.

### Animals

This study was approved by the Korea University Institutional Animal Care & Use Committee (KUIACUC-20151023-1). Eight-week-old male Sprague-Dawley rats, weighing from 250 to 300 g, were purchased from Samtako (Korea) and acclimated for a week, at 24°C with 50-60% relative humidity and 12 h light-dark cycle. During acclimation, rats were fed with standard rodent diet (Samtako, Korea), water *ad libitum*, and housed individually in the polycarbonate cages.

### Preparation of *L. fermentum* LA12 feed

Activated cell cultures 1% (v/v) of *L. fermentum* LA12 was inoculated into MRS and incubated at 37°C for 20 h. Pelleted cells were subsequently collected by centrifugation (8000 g, 15 min, 4°C) and washed thrice with 0.1 M PBS. The pelleted cells of *L. fermentum* LA12 was suspended with 0.1 M PBS, and adjusted to a density of 10<sup>9</sup> CFU/mL prior to use.

### Treatment protocol

After acclimation, thirty-two rats ( $n=8$  /group) were administered intragastrically gavage twice daily with ethanol or dextrose. Ethanol-fed rats received 50% (v/v) ethanol gavage twice daily starting with an initial dose of 2 g/kg/d. This dose was progressively increased every week to a maximum dose of 5 g/kg/d that was continued for 4 wk. Control rats were administered oral gavage with an isocaloric amount of dextrose. These rats were divided into four treatment groups: 1. dextrose; 2. dextrose + *L. fermentum* LA12 (10<sup>9</sup> CFU/mL); 3. ethanol ; 4. ethanol + *L. fermentum* LA12 (10<sup>9</sup> CFU/mL). At 5 weeks, the rats were sacrificed by CO<sub>2</sub> inhalation. Blood samples were immediately collected by cardiac puncture, and serum was obtained via centrifugation (2500 rpm, 10 min) for further analyses. Liver and intestine were then harvested for further use.

### Nitric oxide assay

Nitric oxide level in small intestinal tissues was measured using nitrate/nitrite colorimetric assay kit (Cayman Chemical, USA). Total nitric oxide (NO) level was expressed as the sum of nitrite (NO<sub>2</sub>) and nitrate (NO<sub>3</sub>). Absorbance of samples was measured spectrophotometrically at 550 nm.

### Determination of intestinal permeability

Small intestine was isolated and kept in modified Krebs-Henseleit bicarbonate buffer (KHBB; pH 7.4). A segment of the ileum was first ligated with suture, and 100 µL fluorescein isothiocyanate (FITC)-dextran (molecular weight 4 kDa, FD-4, 40 mg/mL) was injected into the lumen of the isolated distal ileal loop. The other end of the ileum segment was then ligated, and placed in KHBB, and incubated at 37°C for 20 min. The FD-4 that penetrated from the ileum segment into the incubation buffer was measured spectrofluorometrically at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. The fluorescence emission of control group was normalized

as 100%.

### Histology analysis

Fresh liver and small intestinal tissues were harvested and fixed in 10% (v/v) formalin for 24 h at 4°C. The samples were then dehydrated with ethanol (three times 95% (v/v) ethanol for 1 h; twice 100% (v/v) ethanol for 1 h), and dealcoholized twice with xylenes (Sigma-Aldrich, Germany) for 1 h. The dealcoholized samples were then embedded with Paraplast® (Leica Microsystems, Germany), and cut into 5 µm sections using microtome CUT 5062 (Slee medical GmbH, Germany). For histological analysis, one section was stained with hematoxylin and eosin, and examined under the light microscope (Olympus, USA).

### Reverse transcription-polymerase chain reaction analysis

The mRNA expression of small intestinal tight junction proteins and tumor necrosis factor (TNF- $\alpha$ ) was investigated using reverse transcription-polymerase chain reaction. Briefly, total RNA was isolated from samples (liver or intestine) using TRIzol® reagent (Invitrogen, USA) according to manufacturer's procedures. One microgram total RNA was reverse transcribed in 20 µL reaction mixtures with the Super Script® III First-Strand Synthesis System for RT-PCR (Invitrogen, USA) with manufacturer's procedures. The cDNA products were subsequently used for polymerase chain reaction. Oligonucleotides (Macrogen, Korea) sequences used for the amplification of each gene fragment of tight junction proteins and TNF- $\alpha$  were shown in Table 1. The RT-PCR products were then electrophoresed in a 1.5% agarose gel and visualized by ethidium bromide staining. The intensity of each band was determined using Kodak 1D image analysis software (Eastman Kodak Company, USA).

**Table 1. Oligonucleotide primers used in the study**

Gene	Sequence of PCR Primer
ZO-1	Forward: 5'-GCCTCTGCAGTTAAGCAT-3'
	Reverse: 5'-AAGAGCTGGCTGTTTTAA-3'
Occludin	Forward: 5'-CTGTCTATGCTCGTCATCG-3'
	Reverse: 5'-CATTCCCGATCTAATGACGC-3'
Claudin	Forward: 5'-ATGGTAGCCACTTGCCTTC-3'
	Reverse: 5'-TTAGACATGGCACCTTGG-3'
TNF- $\alpha$	Forward: 5'-AAATGGGCTCCCTCTCATCAGTTC-3'
	Reverse: 5'-TCTGCTTGGTGGTTTGCTACGAC-3'
$\beta$ -actin	Forward: 5'-AGAGCTATGAGCTGCCTGAC-3'
	Reverse: 5'-CTGCATCCTGTCAGCGTACG-3'

### Serum biochemical analysis

Endotoxin level in the serum was determined using Pierce Limulus Amebocyte Lysate (LAL) kit (Thermo Scientific, USA). A standard curve of endotoxin was made by using endotoxin of *Escherichia coli*. Absorbance of samples was then measured spectrophotometrically at 405 nm. Additionally, concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the serum were also determined using Infinity AST and Infinity ALT Activity Assay Kits according to the manufacturer's recommendations (Thermo Scientific, USA), respectively. Serum triglyceride was also measured using the Infinity Assay Reagent (Thermo Scientific, USA).

### Myeloperoxidase activity assay

Myeloperoxidase activity in the liver was determined using the Myeloperoxidase Colorimetric Activity Assay Kit (BioVision, USA). Briefly, the liver was homogenized in myeloperoxidase assay buffer, and supernatant was collected by centrifugation (13 000 x g, 30 min, 4°C). Supernatant was subsequently mixed with myeloperoxidase assay buffer and myeloperoxidase substrate. The mixture was then incubated at room temperature for 1 h, and added with tetramethylbenzidine probe. Absorbance of samples was then measured at 412 nm.

### Statistical analyses

Data were analyzed statistically with IBM SPSS software (version 22) (IBM Corp., USA). One-way ANOVA was used to analyze the statistical difference between sample means. The statistical level of significance was preset at  $\alpha=0.05$ . The multiple comparisons of means were assessed by Tukey's test. All data were mean values of replicates from eight separate runs ( $n=8$ ), unless stated otherwise.

## Results and Discussion


### Oral administration of *L. fermentum* LA12 attenuated alcohol-induced intestinal oxidative stress

Specialized intestinal epithelial cells constitute biochemical- and physical barrier surfaces that can sense and respond to external stimuli, which contributed to the maintenance of the fundamental intestinal barrier- and immunoregulatory functions (Peterson and Artis, 2014). However, alcohol may impair epithelial barrier functions by inducing cellular and tissue oxidative damage. NO is a vital, key endogenous oxidant that mediates epithelial cell


injury and intestinal dysfunction. Many studies found that chronic alcohol intake upregulated inducible nitric oxide synthase (iNOS) and produced excessive levels of NO, thereby leading to an intestinal barrier dysfunction in an animal model of ASH (Tang *et al.*, 2009b). In parallel, our study also demonstrated that daily alcohol feeding significantly increased NO-mediated oxidative stress in the intestine (Fig. 1). Interestingly, once-daily administration of *L. fermentum* LA12 for 4 wk significantly decreased ( $p<0.05$ ) intestinal total NO level by 28% in the alcohol-fed rats, but the level remained significantly higher ( $p<0.05$ ) than that of healthy rats (control). Inhibition of intestinal NO production not only reversed diabetes-induced *Klebsiella pneumoniae* liver translocation, but also decreased the severity of alcohol-induced intestinal injury and development of ASH (Lin *et al.*, 2017b; Tang *et al.*, 2009b). Hence, these data suggested that *L. fermentum* LA12 treatment may protect against injurious effect of alcohol on the intestine and liver by attenuating intestinal oxidative stress.

### Oral administration of *L. fermentum* LA12 improved alcohol-induced intestinal hyperpermeability

Purohit *et al.* (2008) have reported that alcohol-induced production of nitric oxide may also contribute to intestinal hyperpermeability to macromolecules. As shown in Fig. 2, intestinal permeability to FITC-dextran in alcohol-fed rats was about 1.7-fold higher than control rats ( $p<0.05$ ), demonstrating that alcohol-induced intestinal oxidative stress further increases intestinal hyperpermeability. In addition to alcohol, acetaldehyde, a highly toxic primary metabolite of alcohol metabolism, has also been proposed to play a potent role in the promotion of intesti-



**Fig. 1. Oral administration of *Lactobacillus fermentum* LA12 decreased alcohol-induced intestinal oxidative stress.** Results are expressed as mean  $\pm$  standard error ( $n=8$ ). <sup>a-c</sup>Means with different lowercase superscript letters are significantly different ( $p<0.05$ ).



**Fig. 2. *Lactobacillus fermentum* LA12 ameliorated alcohol-induced intestinal permeability.** <sup>1</sup>Results are expressed as mean±standard error (n=5). <sup>a-c</sup>Means with different lowercase superscript letters are significantly different ( $p<0.05$ ).

nal permeability (Rao, 2015). Alcohol feeding can promote the overgrowth of intestinal Gram-negative bacteria-encoding bacterial alcohol dehydrogenase and/or aldehyde dehydrogenase, which are capable of metabolizing alcohol into acetaldehyde (Malaguarnera *et al.*, 2014; Nosova *et al.*, 1998). Increased accumulation of acetaldehyde in the lumen may thus subsequently lead to an increase in intestinal hyperpermeability. However, *L. fermentum* LA12 significantly reduced ( $p<0.05$ ) the permeability of intestine in alcohol-fed rats, and the value showed no significant difference compared to that of control groups. Similarly, Forsyth *et al.* (2009) have also demonstrated that once daily administration of probiotic strain, *L. rhamnosus* GG significantly improved alcohol-induced intestinal hyperpermeability, and ameliorated gut-liver injury in the rats. Therefore, this result indicates that *L. fermentum* LA12 treatment could improve the progression of ALD by altering alcohol-induced intestinal hyperpermeability.


#### Oral administration of *L. fermentum* LA12 alleviated alcohol-induced intestinal barrier dysfunction

Several studies have consistently described that rats exposed to alcohol and alcohol-dependent subjects were associated with altered barrier functions and structural epithelial damage (Leclercq *et al.*, 2017). Additionally, “leaky gut” could be an important determinant for the development of alcoholic liver disease; where intestinal permeability only elevated in alcoholics with liver diseases (Keshavarzian *et al.*, 1999). These findings proposed that protection and restitution of gut barrier is crucial to prevent the progression to ALD. Histological analysis in this study showed that alcohol feeding caused abnormality in the small intestinal tissues compared to the control

(Fig. 3A-D). In the control- and groups, the intestine appeared normal with intact epithelial barrier, organized enterocytes, and no signs of inflammation (Fig. 3A-B). However, alcohol feeding caused several signs of jejunal lesions, submucosa damage, and destruction of the tips of the villi, indicating alcohol-induced gut leakiness (Fig. 3C). These observations confirmed that the increased intestinal NO production and intestinal permeability as shown in Figs. 1 and 2 can further contribute to leaky gut. Upon 4 wk treatment, *L. fermentum* LA12 had clearly promoted villous recovery, increased crypt depth and villus height (Fig. 3D), leading to the alleviation of alcohol-induced intestinal barrier dysfunction. Hence, the improved intestinal permeability and decreased intestinal NO production in *L. fermentum* LA12-treated rats may be attributed to the restitution of structure and function of intestinal epithelial barrier.

#### Oral administration of *L. fermentum* LA12 modulated mRNA expression levels of small intestinal tight junction proteins

Intestinal tight junction proteins are multi-complex proteins that play an irreplaceable role in maintaining the intestinal mucosal barrier function. Tight junctions comprise of cytoplasmic scaffolding proteins zonula occludens 1-3 (ZO-1-3), and transmembrane proteins, namely occludin and claudin (Hartsock and Nelson, 2008). These intestinal tight junctions can be affected by exogenous fac-




**Fig. 3. Histological images of hematoxylin and eosin-stained small intestine (200 X) in group.** (A) control, (B) control + LA12, (C) ethanol, (D) ethanol + LA12. After 4 wk, *L. fermentum* LA12 treatment improved alcohol-induced intestinal barrier dysfunction.

tors, including alcohol and high-fat diet. Ingestion of alcohol has been shown to alter the assembly of tight junctions between the epithelial cells by decreasing the expression of occludin, and claudin-1, and ZO-1 (Li *et al.*, 2012; Tang *et al.*, 2008). In order to determine the possible protective mechanisms for alcohol-induced intestinal barrier dysfunction, the effect of *L. fermentum* LA12 on mRNA expression levels of ZO-1, claudin-1, and occludin in the small intestine were evaluated (Fig. 4A). Results revealed that alcohol feeding significantly down-regulated ( $p<0.05$ ) mRNA expression of these three proteins compared to the control. However, we found that *L. fermentum* LA12 treatment significantly up-regulated ( $p<0.05$ ) mRNA expression levels of occludin and claudin in alcohol-fed rats by about 1.1, 0.6-fold, respectively. The mRNA expression level of claudin in alcohol-fed group treated with *L. fermentum* LA12 were also no statistically significant differences from those of dextrose-fed groups. Additionally, the mRNA expression level of claudin in rats fed with dextrose and *L. fermentum* LA12 was significantly higher ( $p<0.05$ ) than dextrose-fed rats, suggesting that *L. fermentum* LA12 can promote and regulate claudin-1 in both healthy- and defective mucosal barrier. These results collectively suggested that *L. fermentum* LA12 not


only restored alcohol-induced intestinal barrier dysfunction, but also helped to maintain normal gut function by modulating intestinal tight junction proteins.

#### Oral administration of *L. fermentum* LA12 improved alcohol-induced endotoxemia, hypertriglyceridemia, and hepatocellular damage

Daily alcohol feeding significantly affected intestinal oxidative stress and permeability (Figs. 1 and 2), thereby allowing intestine-derived endotoxin circulating in the blood (Fig. 5A). Previous studies have collectively suggested that endotoxin is a key cofactor promote liver damage in alcoholic subjects (Rao *et al.*, 2004). However, as shown in Fig. 5A, *L. fermentum* LA12 is capable of reducing serum endotoxin levels ( $p<0.05$ ) in alcohol-fed rats; thereby suggesting that *L. fermentum* LA12 may reduce systemic endotoxemia. Tang *et al.* (2009a) have suggested that attenuation of alcohol-induced oxidative cascade and tight junction structural integrity damage could prevent endotoxemia. Thus, the endotoxemia-limiting effects observed in ethanol + LA12 group could be attributed to the ability of *L. fermentum* LA12 that attenuated intestinal oxidative stress (Fig. 1) and restituted epithelial barrier functions (Figs. 2-4). Furthermore, serum trigly-



**Fig. 4. Effect of *L. fermentum* LA12 treatment on mRNA expression level of intestinal tight junction proteins in alcohol-induced alcoholic steatohepatitis.** Results are expressed as mean±standard error (n=8). <sup>a-d</sup>Means in the same series with different lowercase superscript letters are significantly different ( $p<0.05$ ).



**Fig. 5. *Lactobacillus fermentum* LA12 normalized serum lipid, inflammatory, and liver enzyme parameters in rats of alcohol-induced alcoholic steatohepatitis and inflammation.** (a) Endotoxin, (b) Triglyceride, (c) Aspartate aminotransferase (AST), (d) Alanine aminotransferase (ALT). <sup>1</sup>Results are expressed as mean±standard error (n=8). <sup>a-d</sup>Means with different lowercase superscript letters are significantly different ( $p<0.05$ ).

ceride- (Fig. 5B) and liver enzymes analyses (Fig. 5C-D) demonstrated that alcohol feeding significantly impaired liver functions, in which the damaged hepatocytes spilled the triglyceride, AST and ALT into the blood (Wang *et al.*, 2016). However, *L. fermentum* LA12 treatment significantly reduced ( $p<0.05$ ) the serum level of triglyceride, AST, and ALT by 50.6%, 18%, and 24% respectively; in alcohol-fed rats. These results indicate that *L. fermentum* LA12 may play a protective role against liver damage.


#### Oral administration of *L. fermentum* LA12 attenuated alcohol-induced hepatic-oxidative stress and TNF- $\alpha$ production

Oxidative stress and inflammation are key contributors to the progression of ASH. Myeloperoxidase (MPO) is a neutrophil enzyme involved in processing phagocytic material, as well as generates oxidants participate in molecular events responsible for various disease development. Chronic alcohol intake promoted hepatic MPO-generated oxidative stress, which can subsequently stimulate hepatic TNF- $\alpha$  production that lead to the development of ASH (Zhou *et al.*, 2003). This was in tandem with our study, where alcohol treatment increased both hepatic-

MPO activity (Fig. 6A) and hepatic mRNA expression level of TNF- $\alpha$  (Fig. 6B) in the rats. Interestingly, *L. fermentum* LA12 treatments for 4 wk significantly decreased ( $p<0.05$ ) MPO activity and down-regulated mRNA expression of TNF- $\alpha$  in the liver. Lin *et al.* (2017) have proposed that hydrogen-rich water associated with antioxidant and anti-inflammatory effects can improve liver functions, thereby alleviating ethanol-induced fatty liver in mice. Altogether, these data suggested that *L. fermentum* LA12 treatment could improve liver function by ameliorating alcohol-induced oxidative stress and inflammation in the liver, subsequently preventing the leakage of liver enzymes (AST and ALT; Fig. 5) into the bloodstream.


#### Oral administration of *L. fermentum* LA12 alleviated alcohol-induced hepatic steatosis

Alcohol can induce a wide spectrum of histologic changes in the liver. It has been reported that macro-vesicular steatosis is the first and most common histological change observed in 90% of alcoholic subjects (Mathurin *et al.*, 2007). Fortunately, early formation of macro-vesicular lipid droplets is still manageable by following a prolonged period of abstinence from alcohol and/or prophylaxis



**Fig. 6. *Lactobacillus fermentum* LA12 treatment attenuated alcohol-induced hepatic-oxidative stress and inflammation in alcohol-induced alcoholic steatohepatitis.** (A) Hepatic MPO activity, (B) Hepatic mRNA expression level of TNF- $\alpha$ . <sup>1</sup>Results are expressed as mean $\pm$ standard error (n=8). <sup>a-c</sup>Means with different lowercase superscript letters are significantly different ( $p < 0.05$ ).

(Frazier *et al.*, 2011). Changes in the histological structure of the liver of four treatment groups in this study were illustrated in Fig. 7A-D. As shown in Fig. 7C, chronic alcohol intake result in the stimulation of hepatic neutrophil infiltration and formation of macro-vesicular lipid droplets, and subsequently induce liver injury and alter liver function (Figs. 5, 6). However, four-week *L. fermentum* LA12 treatment decreased neutrophil infiltration and formation of macro-vesicular lipid droplets in the liver of alcohol-fed rats, and showed no obvious histological difference as compared to the healthy rats (Fig. 7D). Alcohol intake often stimulated neutrophil transmigration to hepatocytes, and neutrophil accumulation in the liver subsequently exacerbates the liver damage by up-regulating inflammatory responses and increasing oxidative stress (Ramaiah and Jaeschke, 2007). These results indicate that administration of *L. fermentum* LA12 could improve hepatic steatosis via anti-inflammatory and anti-oxidant ac-



**Fig. 7. Histological images of hematoxylin and eosin-stained liver tissues (200 X) in group.** (A) control, (B) control + LA12, (C) ethanol, (D) ethanol + LA12. After 4 wk, *L. fermentum* LA12 treatment improved alcohol-induced liver injury.

tions.

## Conclusion

Taken together, results in this study suggested the potential use of *L. fermentum* LA12 for the prevention of alcoholic steatohepatitis via gut-liver axis. Four-week administration of *L. fermentum* LA12 was capable of stimulating restitution in intestinal barrier function and reducing alcohol-induced inflammatory mediators, thereby attenuating leaky gut and liver damage, and preventing the progression of ASH.

## Acknowledgements

This work was financially supported by the grants funded by the Chong Kun Dang Bio and Korea University.

## References

- Bang, H. A., Kwon, Y. H., Lee, M. J., and Lee, W. C. (2015) Trends in the epidemiological aspects and mortality of alcoholic liver disease in Korea in the decade between 2000 and 2009. *J. Clin. Med. Res.* **7**, 91-96.
- Frazier, T. H., Stocker, A. M., Kershner, N. A., Marsano, L. S., and McClain, C. J. (2011) Treatment of alcoholic liver disease. *Therap. Adv. Gastroenterol.* **4**, 63-81.
- Forsyth, C. B., Farhadi, A., Jakate, S. M., Tang, Y., Shaikh, M., and Keshavarzian, A. (2009) *Lactobacillus* GG treatment amelio-

- rates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. *Alcohol* **43**, 163-172.
- Hartssock, A. and Nelson, W.J. (2008) Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. *Biochim. Biophys. Acta* **1778**, 660-669.
- Hill, C., Guatner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., Salminen, S., Calder, P. C., and Sanders, M. E. (2014) Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* **11**, 506-514.
- Keshavarzian, A., Holmes, E. W., Patel, M., Iber, F., Fields, J. Z., and Pethkar, S. (1999) Leaky gut in alcoholic cirrhosis: A possible mechanism for alcohol-induced liver damage. *Am. J. Gastroenterol.* **94**, 200-207.
- Leclercq, S., de Timary, P., Delzenne, N. M., and Stärkel, P. (2017) The link between inflammation, bugs, the intestine and the brain in alcohol dependence. *Transl. Psychiatry* **7**, e1048.
- Lee, J., Yun, H. S., Cho, K. W., Oh, S., Kim, S. H., Chun, T., Kim, B., and Whang, K. Y. (2011) Evaluation of probiotic characteristics of newly isolated *Lactobacillus* spp.: Immune modulation and longevity. *Int. J. Food Microbiol.* **148**, 80-86.
- Li, X., Akhtar, S., and Choudhry, M. A. (2012) Alteration in intestine tight junction protein phosphorylation and apoptosis is associated with increase in IL-18 levels following alcohol intoxication and burn injury. *Biochim. Biophys. Acta* **1822**, 196-203.
- Lin, C. P., Chuang, W. C., Lu, F. J., and Chen, C. Y. (2017) Antioxidant and anti-inflammatory effects of hydrogen-rich water alleviate ethanol-induced fatty liver in mice. *World J. Gastroenterol.* **23**, 4920-4934.
- Lin, S., Chung, P., Wu, Y., Fung, C., Hsu, C., and Chen, L. (2017) Inhibition of nitric oxide production reverses diabetes-induced Kupffer cell activation and *Klebsiella pneumoniae* liver translocation. *PLoS One* **12**, e0177269.
- Louvet, A. and Mathurin, P. (2015) Alcoholic liver disease: Mechanisms of injury and targeted treatment. *Nat. Rev. Gastroenterol. Hepatol.* **12**, 231-242.
- Lu, K. H., Liu, C. T., Raghu, R., and Sheen, L. Y. (2012) Therapeutic potential of Chinese herbal medicines in alcoholic liver disease. *J. Tradit. Complement. Med.* **2**, 115-122.
- Mathruin, P., Beuzin, F., Louvet, A., Carrie-Ganne, N., Balian, A., Trinchet, J. C., Dalsoglio, D., Prevot, S., and Naveau, S. (2007) Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. *Aliment. Pharmacol. Ther.* **25**, 1047-1054.
- Nosova, T., Jokelainen, K., Kaihovaara, P., Jousimies-Somer, H., and Salaspuro, M. (1998) Characteristics of aldehyde dehydrogenases of certain aerobic bacteria representing human colonic flora. *Alcohol.* **33**, 273-280.
- Peterson, L.W. and Artis, D. (2014) Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. *Nat. Rev. Immunol.* **14**, 141-153.
- Purohit, V., Bode, J. C., Bode, C., Brenner, D. A., Choudhry, M. A., Hamilton, F., Kang, Y. J., Keshavarzian, A., Rao, R., Sartor, R. B., Swanson, C., and Turner, J. R. (2008) Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. *Alcohol* **42**, 349-361.
- Ramaiah, S. K. and Jaeschke, H. (2007) Role of neutrophils in the pathogenesis of acute inflammatory liver injury. *Toxicol. Pathol.* **35**, 757-766.
- Rao, R. K., Seth, A., and Sheth, P. (2004) Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. *Am. J. Physiol. Gastrointest. Liver Physiol.* **286**, 881-884.
- Rao, R. (2015) Endotoxemia and gut barrier dysfunction in alcoholic liver disease. *Hepatology* **50**, 638-644.
- Segawa, S., Wakita, Y., Hirata, H., and Watari, J. (2008) Oral administration of heat-killed *Lactobacillus brevis* SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. *Int. J. Food Microbiol.* **128**, 371-377.
- Szabo, G. (2015) Gut-liver axis in alcoholic liver disease. *Gastroenterology* **148**, 30-36.
- Tang, Y., Banan, A., Forsyth, C. B., Fields, J. Z., Lau, C. K., Zhang, L. J., and Keshavarzian, A. (2008) Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. *Alcohol Clin. Exp. Res.* **32**, 355-364.
- Tang, Y., Forsyth, C. B., Banan, A., Fields, J. Z., and Keshavarzian, A. (2009a) Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. *J. Pharmacol. Exp. Ther.* **329**, 952-958.
- Tang, Y., Forsyth, C. B., Farhadi, A., Rangan, J., Jakate, S., Shaikh, M., Banan, A., Fields, J. Z., and Keshavarzian, A. (2009b) Nitric oxide mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. *Alcohol Clin. Exp. Res.* **33**, 1220-1230.
- Wang, F., Zhang, Y. J., Zhou, Y., Li, Y., Zhou, T., Zheng, J., Zhang, J. J., Li, S., Xu, D. P., and Li, H. B. (2016) Effects of beverages on alcohol metabolisms: Potential health benefits and harmful impacts. *Int. J. Mol. Sci.* **17**, 354.
- World Health Organization. (2014) Global status report on alcohol and health. WHO Press, Switzerland, pp. 1-25.
- Zhou, Z., Wang, L., Song, Z., Lambert, J. C., McClain, C. J., and Kang, J. (2003) A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF- $\alpha$  production. *Am. J. Pathol.* **163**, 1137-1146.